

Notice: This document, a translation of a notice in Japanese, is purely for information purposes, and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

June 3, 2015

To Our Shareholders:

Masayuki Mitsuka
President & Representative Director
Chief Executive Officer
Mitsubishi Tanabe Pharma Corporation
3-2-10, Dosho-machi, Chuo-ku, Osaka, Japan

**Partial Correction to
Notice of Convocation of the 8th Ordinary General Meeting of Shareholders**

The Notice of Convocation of the 8th Ordinary General Meeting of Shareholders, which we have sent you as of May 28, 2015, has come to require partial correction. We express our sincere apology for any inconvenience this may cause you and would like to inform you of the correction via our website, as follows.

1. Corrected part

Notice of Convocation of the 8th Ordinary General Meeting of Shareholders
Attached Documents page 22
②Matters Related to Subsidiaries

2. Content of Correction (Underlined)

(Before correction)

Company Name : Tai Tien Pharmaceuticals Co., Ltd.
Investment ratio (%) : 100.0

(After correction)

Company Name : Tai Tien Pharmaceuticals Co., Ltd.
Investment ratio (%) : 65.0

End